HEIDELBERG PHARMA AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.07 EUR | -0.32% |
|
+1.65% | -17.65% |
| Apr. 23 | Transcript : Heidelberg Pharma AG - Special Call | |
| Mar. 27 | Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâs pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.08
EUR
Average target price
11.3
EUR
Spread / Average Target
+266.88%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.65% | 154M | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +2.39% | 22.19B | |
| -16.16% | 21.33B | |
| -6.82% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
- Stock Market
- Equities
- HPHA Stock
- News Heidelberg Pharma AG
- Heidelberg Pharma Unit Signs License Deal With Japan's Takeda For Antibody Targeted Amanitin Conjugate
